Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24010133 | 0.84 | STAT3 (0.44) | LMNAHPGDHTR2CRAB9AMAPT | |
| SCHEMBL25822231 | 0.83 | NPC1 (0.49) | LMNAHPGDATMRXFP1NPC1 | |
| SCHEMBL25822238 | 0.79 | RXFP1 (0.52) | LMNARXFP1NPC1MAPTKDM4E | |
| SCHEMBL24010367 | 0.77 | STAT3 (0.42) | LMNAHPGDHTR2CNPC1RAB9A | |
| SCHEMBL25820810 | 0.76 | FAAH (0.43) | LMNAHPGDHTR2CRAB9AMAPT | |
| SCHEMBL8614711 | 0.75 | ALDH1A1 (0.61) | LMNAHPGDNPC1RAB9AMAPT | |
| SCHEMBL24010132 | 0.73 | DNMT1 (0.44) | MAPTPOLBMAPK1KDM4EALDH1A1 | |
| SCHEMBL30290895 | 0.73 | DNMT1 (0.44) | MAPTPOLBMAPK1KDM4EALDH1A1 | |
| SCHEMBL7352861 | 0.72 | PDE4B (0.69) | ATMMAPTMITF | |
| SCHEMBL25821827 | 0.72 | BRAF (0.69) | LMNAHPGDATMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | LMNA 2015/4885HPGD 2768/4885ATM 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.